Inventor · disambiguated record
Bruce A. Hay
Also filed as: HAY BRUCE A · HAY BRUCE ALLAN
38 granted patents·30 pending applications·252 citations·filing 1988–2025
97Inventor score
Top patents by PatentIndex Score
68 records- 0196US10961204B1Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumorsNANOPHARMACEUTICALS LLC·Filed 2020·Granted Mar 30, 2021·4 cites·18 claims
- 0296US5013571AMethods for making tetrahydroisoalpha and hexahydroisoalpha acidsPFIZER·Filed 1990·Granted May 7, 1991·128 cites·33 claims
- 0392US11896646B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2022·Granted Feb 13, 2024·1 cites·16 claims
- 0490US6720330B2Somatostatin antagonists and agonists that act at the SST subtype 2 receptorPFIZER·Filed 2001·Granted Apr 13, 2004·25 cites·24 claims
- 0588US6696418B1Somatostatin antagonists and agonists that act at the SST subtype 2 receptorPFIZER·Filed 2000·Granted Feb 24, 2004·18 cites·23 claims
- 0687US11679141B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Jun 20, 2023·1 cites·9 claims
- 0787US8728529B2Nanoparticle contrast agents for diagnostic imagingBUTTS MATTHEW DAVID·Filed 2008·Granted May 20, 2014·6 cites·22 claims
- 0886US11744874B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2020·Granted Sep 5, 2023·1 cites·9 claims
- 0986US10570200B2Antibody-mediated immunocontraceptionCALIFORNIA INST OF TECHN·Filed 2014·Granted Feb 25, 2020·5 cites·21 claims
- 1086US8889103B2Diagnostic agent composition and associated methods thereofHAY BRUCE ALLAN·Filed 2010·Granted Nov 18, 2014·7 cites·10 claims
- 1186US8574549B2Nanoparticle contrast agents for diagnostic imagingBUTTS MATTHEW DAVID·Filed 2008·Granted Nov 5, 2013·7 cites·19 claims
- 1285US12311010B2Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Granted May 27, 2025·0 cites·14 claims
- 1385US11801304B2Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Oct 31, 2023·1 cites·14 claims
- 1485US2024123028A1Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof CNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1582US6495589B2Somatostatin antagonists and agonists that act at the SST subtype 2 receptorPFIZER·Filed 2000·Granted Dec 17, 2002·18 cites·21 claims
- 1682US2023277621A1Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1779US12059470B2Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Granted Aug 13, 2024·0 cites·18 claims
- 1878US12213468B2Population control using engineered translocationsCALIFORNIA INST OF TECHN·Filed 2020·Granted Feb 4, 2025·1 cites·14 claims
- 1978US10966414B2Population control using engineered translocationsCALIFORNIA INST OF TECHN·Filed 2016·Granted Apr 6, 2021·3 cites·12 claims
- 2078US2025032620A1Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2177US12157883B2DNA sequence modification-based gene driveCALIFORNIA INST OF TECHN·Filed 2018·Granted Dec 3, 2024·2 cites·8 claims
- 2277US9399075B2Nanoparticle contrast agents for diagnostic imagingGEN ELECTRIC·Filed 2013·Granted Jul 26, 2016·1 cites·11 claims
- 2376US11965172B2DNA sequence modification-based gene driveCALIFORNIA INST OF TECHN·Filed 2019·Granted Apr 23, 2024·2 cites·11 claims
- 2476US2024366772A1Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2575US2025313531A1Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2675US2025177484A1Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor (TLR) Agonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2775US2024050575A1Formulated and/or co-formulated liposome compositions containg TGFb antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2874US9468692B2Labeled molecular imaging agents and methods of useGEN ELECTRIC·Filed 2014·Granted Oct 18, 2016·1 cites·8 claims
- 2973US11833209B2Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Dec 5, 2023·0 cites·15 claims
- 3071US2024425845A1Dna sequence modification-based gene driveCALIFORNIA INST OF TECHN·Filed 2024·Application pending·0 cites
- 3170US9205155B2Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agentsBALES BRIAN CHRISTOPHER·Filed 2009·Granted Dec 8, 2015·0 cites·3 claims
- 3268US12286403B2Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2020·Granted Apr 29, 2025·0 cites·19 claims
- 3368US11186551B2Composition of scalable thyrointegrin antagonists with improved retention in tumorsNANOPHARMACEUTICALS LLC·Filed 2021·Granted Nov 30, 2021·0 cites·12 claims
- 3467US2025122512A1Cleave and rescue gamete killers for gene drive in plantsCALIFORNIA INST OF TECHN·Filed 2024·Application pending·0 cites
- 3565US2024376212A1Alpha v-integrin targeted small molecule drug conjugatesTARGETTHERA LLC·Filed 2023·Application pending·0 cites
- 3662US2010278748A1Nanoparticle contrast agents for diagnostic imagingGEN ELECTRIC·Filed 2009·Application pending·0 cites
- 3762US2010278734A1Nanoparticle contrast agents for diagnostic imagingGEN ELECTRIC·Filed 2009·Application pending·0 cites
- 3862US2024108732A1Formulated and/or Co-Formulated Lipid Nanocarriers Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3961US9846206B2Systems and methods for magnetic material imagingGEN ELECTRIC·Filed 2013·Granted Dec 19, 2017·2 cites·12 claims
- 4061US2010166664A1Nanoparticle contrast agents for diagnostic imagingGEN ELECTRIC·Filed 2008·Application pending·0 cites
- 4160US5013572ASteam stripping of odor forming impurities from hop flavorsPFIZER·Filed 1990·Granted May 7, 1991·12 cites·11 claims
- 4259US11723888B2Polymer conjugated thyrointegrin antagonistsNANOPHARMACEUTICALS LLC·Filed 2021·Granted Aug 15, 2023·0 cites·13 claims
- 4359US2004157834A1Somatostatin antagonists and agonists that act at the SST subtype 2 receptorPFIZER·Filed 2004·Application pending·0 cites
- 4458US2004058877A1Somatostatin antagonists and agonists that act at the sst subtype 2 receptorPFIZER·Filed 2003·Application pending·0 cites
- 4558US2023226031A1Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4657US2022401451A1Formulated and/or co-formulated compositions containing A2aR antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4756US9827335B2Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agentsGEN ELECTRIC·Filed 2015·Granted Nov 28, 2017·0 cites·15 claims
- 4855US9468693B2Labeled molecular imaging agents and methods of useGEN ELECTRIC·Filed 2014·Granted Oct 18, 2016·0 cites·7 claims
- 4952US4851548ASuperior catalysts for preparation of 3-amino-2,2,4,4-tetramethylthietane via the Leuckart reactionPFIZER·Filed 1988·Granted Jul 25, 1989·3 cites·6 claims
- 5051US2002016298A1Somatostatin antagonists and agonists that act at the sst subtype 2 receptorFiled 2000·Application pending·0 cites
Showing the top 50 of 68 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →